IT
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution
We are proud to announce that Hartwig Medical Foundation has received CE certification under the European In Vitro Diagnostic Regulation …
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
Hartwig and Ultima Expand Collaboration to Advance WGS in Oncology Care
Hartwig and Ultima strengthen collaboration on whole‑genome sequencing Hartwig Medical Foundation to adopt Ultima Genomics’ UG200 sequencing system to accelerate …
From Spreadsheets to Digital Convenience: Hartwig Goes Live With Its Customer Portal
Hartwig Medical Foundation (Hartwig) recently launched its new portal for submitting requests for WGS analysis. For hospitals, this is an important enhancement to …
Arno de Quaasteniet new member of the board of Hartwig Medical Foundation
Hartwig Medical Foundation is pleased to announce that as of October 1, 2024, Arno de Quaasteniet (1977) has been appointed …
Breast cancer awareness month
October is the international breast cancer awareness month. Breast cancer is the second most common type of cancer, and the …
Hartwig tools now available as a nextflow nf-core pipeline called oncoanalyser
The University of Melbourne Centre for Cancer Research (UMCCR) Genomics Platform Group, led by Professor Oliver Hofmann, has collaborated with …
Screening for T cells that already fight the tumor: Hartwig’s pipeline in practice
By Laura Nederveen In the search for more effective cancer treatments, Alena Gros and her team at Vall d’Hebron Institute …
Join us for an evening of Healthcare Tech innovation with Hartwig Medical Foundation and GCUG
Calling all software developers and tech enthusiasts 🚀 Hartwig Medical Foundation partners with Google Cloud User Group (GCUG) to bring …
Catalog makes Hartwig Medical Database easily searchable
Hartwig Medical Foundation maintains a catalog of the Hartwig Medical Database with whole-genome data on full tumor genomes: https://catalog.hartwigmedicalfoundation.nl. The …
Collaboration between Hartwig and CKB makes both parties stronger
Hartwig Medical Foundation has worked with The Jackson Laboratory (JAX) Clinical Knowledgebase (CKB) team since 2020, to the benefit of …
Blogs
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.